Paroxysmal nocturnal hemoglobinuria from bench to bedside

Area of Science:

• Hematology
• Genetics
• Immunology

Background:

• Paroxysmal nocturnal hemoglobinuria (PNH) is a rare hematologic disorder with diverse clinical presentations.
• Recent advances have elucidated the genetic basis and led to targeted therapies for PNH.
• The disease originates from a somatic mutation in the PIG-A gene within hematopoietic stem cells (HSCs).

Purpose of the Study:

• To explain the pathogenesis of PNH, focusing on the PIG-A gene mutation and its consequences.
• To describe the diagnostic utility of aerolysin and its variants in identifying PNH.
• To introduce eculizumab as a novel therapeutic agent for PNH.

Main Methods:

• Investigated the role of the PIG-A gene in glycosylphosphatidylinositol (GPI) anchor biosynthesis.
• Examined the absence of GPI-anchored proteins, specifically CD55 and CD59, on PNH cells.
• Utilized aerolysin and its fluorescinated variant (FLAER) as diagnostic tools.
• Reviewed the mechanism of action for eculizumab, a C5 inhibitor.

Main Results:

• PIG-A mutations impair GPI anchor synthesis, leading to absent CD55 and CD59 on PNH cells.
• Absence of CD55/CD59 results in complement-mediated hemolysis and release of free hemoglobin.
• FLAER effectively binds to GPI-anchored proteins, enabling PNH diagnosis.
• Eculizumab demonstrates efficacy in treating PNH by inhibiting complement C5.

Conclusions:

• PNH pathogenesis involves a PIG-A mutation leading to complement dysregulation and hemolysis.
• FLAER is a valuable diagnostic reagent for PNH.
• Eculizumab represents a breakthrough targeted therapy for PNH, improving patient outcomes.